Who can use Defitelio(Defibrotide)?

Defitelio is indicated for the treatment of hepatic veno-occlusive disease (VOD) with associated renal or pulmonary dysfunction in both adult and pediatric patients following hematopoietic stem-cell transplantation (HSCT).

Indicated Patient Population

Defitelio (defibrotide sodium) is approved for use in adult and pediatric patients who develop hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), after hematopoietic stem-cell transplantation (HSCT) and have accompanying renal or pulmonary dysfunction. Treatment is contraindicated in patients with active bleeding, hypersensitivity to the drug, or those requiring concomitant systemic anticoagulant or fibrinolytic therapy.